Skip to main content

Table 6 Biomarker levels in control and KD-treated breast cancer patients

From: Does a ketogenic diet have beneficial effects on quality of life, physical activity or biomarkers in patients with breast cancer: a randomized controlled clinical trial

Variable

Trial Arms

Baseline

Midpoint

12 weeks

p- value midpoint vs BL

p-value 12wks vs midpoint

p-value 12wks vs BL

Lactate

KD

13.3 ± 11

10.8 ± 4

10.7 ± 3

1

1

1

Control

13.8 ± 4

14.7 ± 6

13.3 ± 4

0.94

0.93

1

MD (95% CI)

−0.51(−5.3,4.2)

−3.8 (−7,-0.7)

−2.6 (−4.8,-0.35)

1

0.01

0.02

LDH (u/l)

KD

680 ± 643

666 ± 770

535 ± 517

1

0.48

0.58

Control

706 ± 560

627 ± 556

472 ± 148

1

0.36

0.12

MD (95% CI)

−25 (− 374,323)

39 (− 330,409)

62 (− 145,271)

1

1

1

Ammonia (mcg/dl)

KD

58 ± 17

60 ± 17

66 ± 15

1

1

0.69

Control

75 ± 27

71 ± 36

75 ± 24

1

0.92

1

MD (95% CI)

−17 (−30,3.9)

−11(−29,6.9)

−9 (−20.8,2.4)

0.03

0.43

0.49

Albumin (g/dl)

KD

4.5 ± 0.33

4.5 ± 0.26

4.5 ± 0.33

1

1

1

Control

4.4 ± 0.43

4.5 ± 0.37

4.5 ± 0.37

1

1

1

MD (95% CI)

0.08(−0.13,0.29

0.04-(0.15,0.24)

0.04 (−0.16,0.2)

1

1

1

ALP

KD

197 ± 126

169 ± 76

149 ± 71

1

1

0.99

Control

325 ± 375

333 ± 440

240 ± 164

1

0.11

0.51

MD (95% CI)

− 127(− 285,29)

−164(−372,44)

−90(− 162,-19)

0.19

0. 13*

0.02*

K (meq/l)

KD

4.2 ± 0.39

4.1 ± 0.43

4.1 ± 0.33

1

0.46

0.13

Control

4.2 ± 0.35

4.3 ± 0.38

4.2 ± 0.37

1

1

0.75

MD95% CI

−0.05 (− 0.26,0.15)

−0.14)0.41,0.12(

−0.10 (−0.29,0.08)

1

0.69

0.88

P (mg/Dl)

KD

4 ± 0.71

3.9 ± 0.66

4.4 ± 0.88

1

0.05

0.06

Control

4.1 ± 0.92

4.2 ± 0.52

4.3 ± 0.65

1

1

1

MD95% CI

−0.17 (− 0.63,0.28(

−0.24 (0.63,0.14)

0.07 (−0.34,0.50(

1

0.93

1

Mg (mg/dL)

KD

2.1 ± 0.19

2 ± 0.13

2 ± 0.19

1

1

1

Control

2.1 ± 0.21

2 ± 0.19

2 ± 0.23

0.43

0.82

1

MD95% CI

−0.001 (− 0.11,0.11)

0.07 (− 0.03,0.18)

−0.02 (−0.14,0.09)

1

0.76

1

Ca (mg/dl)

KD

9.4 ± 1.2

9.4 ± 0.80

9.3 ± 0.59

0.37

1

0.16

Control

9/4 ± 0.95

9.2 ± 0.78

9.4 ± 0.56

0.84

0.85

1

MD95% CI

0.36

0.21

−0/10

0.42

1

1

Na (meq/l)

KD

146 ± 43

140 ± 3

140 ± 2

0.83

1

0.79

Control

138 ± 2.8

138 ± 2

133 ± 24

1

0.80

0.80

MD 95% CI

7.9(−9.8,25.7)

1.9 (0.19,3.6)

7 (−2.3,17.3)

0.56

1

0.63

  1. BL Baseline, Midpoint: 1st follow-up or week 6, 12 weeks: 12 weeks or last follow-up, MD Mean Difference, CI Confidence Interval Analysis type: Repeated measure, all p values were calculated based on Bonferroni correction for multiple comparisons * Ancova: Adjusted for base line value and cancer type